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with that of the DENV-2 strains from the 1983 (accession 
no. EU056810) and 1986 (accession nos. HM234642 and 
GU131843) epidemics in Burkina Faso. Strains of DENV-2 
from the 2005 epidemic in Ghana (accession no. EU005258) 
shared 95% identity with that of the patient reported here.
Phylogenetic analysis indicated that the dengue virus 
genome sequence in this case is highly homologous with 
recent strains in Africa, especially from the 2016, 1986, and 
1983 outbreaks in Burkina Faso. Similar strains of DENV-
2 have repeatedly caused outbreaks in West Africa (8). As 
of April 2017, DENV-2 and DENV-3 have been isolated 
from patients in the ongoing outbreak in Abidjan (10). Al-
though no cases have been reported outside Abidjan, the 
case reported here may be a sentinel case, serving as an 
alert to the possibility of disease spread outside Africa.
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To the Editor: The recent etymologia article on 
Creutzfeldt-Jakob disease by Henry and Murphy (1) does 
not accurately reflect current understanding of the con-
tributions of Creutzfeldt and Jakob. Although Jakob had 
reported that Creutzfeldt’s earlier case was a “nosologi-
cally very closely connected if not identical affection” (2), 
Creutzfeldt himself later reported that “his case did not bear 
any resemblance to the cases described by Jakob” (3). As 
discussed by neuropathologist Edgar Peirson Richardson, 
Jr., in 1977, “Did Creutzfeldt and Jakob describe CJD? … 
Creutzfeldt probably did not—Jakob to the contrary not-
withstanding—and Creutzfeldt is said to have disagreed 
with the identification of his case with Jakob’s cases. Ja-
kob’s cases, on the other hand, can more readily be fitted 
into current concepts of the disease without undue strain” 
(4). In 1982, neuropathologist Colin L. Masters and pedia-
trician D. Carleton Gajdusek concurred with Richardson: 
“We agree with Richardson (1977) that Creutzfeldt’s case 
probably can be excluded from classification as a spongi-
form encephalopathy on the basis of his own clinical and 
pathological descriptions, although a specific alternative 
LETTER
diagnosis cannot be made” (5). In a later article, Richardson 
and Masters further noted that Creutzfeldt’s case showed 
no indication of spongiform change, and the character of 
the lesions was not characteristic of “CJD” (6). In contrast, 
Jakob clearly described cases of “CJD”: based on reex-
amination of the original pathologic slides preserved at the 
University of Hamburg, several of Jakob’s cases were con-
sistent with the clinical picture of “CJD” and showed char-
acteristic pathologic findings of spongiform encephalopa-
thy (5). Finally, although Walther Spielmeyer first used the 
term “Creutzfeldt-Jakob disease” in 1922, his decision to 
emphasize Creutzfeldt was likely because Creutzfeldt was 
then working in Spielmeyer’s laboratory; other early terms 
for the disease gave credit preferentially or solely to Jakob.
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